Aptevo Reports 87% Clinical Benefit Rate and 81% Remission in Frontline AML Trial RAINIER

Aptevo Therapeutics Inc.

Across 31 evaluable frontline AML patients, mipletamig combo showed 87% clinical benefit rate and 81% remission (CR/CRi), outperforming VIALE-A benchmark of 66.4%.
Phase 1b dose optimization trial on track for 2026 completion; final cohorts 6 and 7 under enrollment with Cohort 6 nearing completion.
65% achieved complete remission vs 37% historical benchmark; 52% of remissions were MRD-negative.
No cytokine release syndrome reported; 6 patients proceeded to allogeneic stem cell transplant.
Phase 2 dose selection and regulatory interaction planned after dataset completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.